Logo image of FYB.DE

FORMYCON AG (FYB.DE) Stock Price, Quote, News and Overview

FRA:FYB - Deutsche Boerse Ag - DE000A1EWVY8 - Common Stock - Currency: EUR

33.2  +0.6 (+1.84%)

FYB.DE Quote, Performance and Key Statistics

FORMYCON AG

FRA:FYB (2/18/2025, 7:00:00 PM)

33.2

+0.6 (+1.84%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High64.4
52 Week Low27.55
Market Cap586.31M
Shares17.66M
Float11.19M
Yearly DividendN/A
Dividend YieldN/A
PE8.3
Fwd PE145.64
Earnings (Next)03-27 2025-03-27/amc
IPO12-20 2010-12-20


FYB.DE short term performance overview.The bars show the price performance of FYB.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

FYB.DE long term performance overview.The bars show the price performance of FYB.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of FYB.DE is 33.2 EUR. In the past month the price decreased by -38.86%. In the past year, price decreased by -34.52%.

FORMYCON AG / FYB Daily stock chart

FYB.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 19.39 331.06B
AMG.DE AMGEN INC 14.74 149.74B
GIS.DE GILEAD SCIENCES INC 23.05 126.37B
1VRTX.MI VERTEX PHARMACEUTICALS INC 1627.14 117.04B
1GILD.MI GILEAD SCIENCES INC 21.01 115.18B
VX1.DE VERTEX PHARMACEUTICALS INC 1577.86 113.50B
ARGX.BR ARGENX SE N/A 37.30B
22UA.DE BIONTECH SE-ADR N/A 27.88B
IDP.DE BIOGEN INC 8.31 19.05B
0QF.DE MODERNA INC N/A 13.31B
1MRNA.MI MODERNA INC N/A 12.02B
GLPG.AS GALAPAGOS NV 8.23 1.70B

About FYB.DE

Company Profile

FYB logo image Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 239 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Company Info

FORMYCON AG

Fraunhoferstrasse 15

Martinsried BAYERN DE

Employees: 239

Company Website: https://www.formycon.com/

Investor Relations: http://www.formycon.com/investors/financial-reports/

Phone: 4989864667100

FYB.DE FAQ

What is the stock price of FYB.DE?

The current stock price of FYB.DE is 33.2 EUR.


What is the symbol for FORMYCON AG stock?

The exchange symbol of FORMYCON AG is FYB and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is FYB.DE stock listed?

FYB.DE stock is listed on the Deutsche Boerse Ag exchange.


Is FYB.DE a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for FYB.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of FYB.DE.


Does FYB.DE stock pay dividends?

FYB.DE does not pay a dividend.


When does FYB.DE stock report earnings?

FYB.DE will report earnings on 2025-03-27, after the market close.


What is the Price/Earnings (PE) ratio of FYB.DE?

The PE ratio for FYB.DE is 8.3. This is based on the reported non-GAAP earnings per share of 4 and the current share price of 33.2 EUR.


FYB.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

FYB.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to FYB.DE. FYB.DE has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FYB.DE Financial Highlights

Over the last trailing twelve months FYB.DE reported a non-GAAP Earnings per Share(EPS) of 4. The EPS decreased by 243.1% compared to the year before.


Industry RankSector Rank
PM (TTM) 105.09%
ROA 6.74%
ROE 11.09%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-616.42%
Sales Q2Q%-38.59%
EPS 1Y (TTM)243.1%
Revenue 1Y (TTM)-11.42%

FYB.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to FYB.DE. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -125.43% and a revenue growth -22.49% for FYB.DE


Ownership
Inst Owners10.81%
Ins Owners5.92%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.33
Price Target93.04 (180.24%)
EPS Next Y-125.43%
Revenue Next Year-22.49%